当前位置: 首页 >> 检索结果
1. Optical Coherence Tomography Versus Angiography Alone to Guide PCI for Complex Lesions: A Meta-Analysis of Randomized Controlled Trials.
作者: Chidubem Ezenna.;Mrinal Murali Krishna.;Meghna Joseph.;Sammudeen Ibrahim.;Vinicius Pereira.;Ancy Jenil-Franco.;Michael G Nanna.;Sripal Bangalore.;Andrew M Goldsweig.
来源: Circ Cardiovasc Interv. 2025年18卷5期e015141页
Optical coherence tomography (OCT) provides high-resolution intracoronary imaging. However, whether the addition of OCT to angiography to guide percutaneous coronary intervention (PCI) of complex lesions affects clinical outcomes is debated.
2. Systematic Review, Meta-Analysis, and Population Study to Determine the Biologic Sex Ratio in Dilated Cardiomyopathy.
作者: Natalie Bergan.;Ishika Prachee.;Lara Curran.;Kathryn A McGurk.;Chang Lu.;Antonio de Marvao.;Wenjia Bai.;Brian P Halliday.;John Gregson.;Declan P O'Regan.;James S Ware.;Upasana Tayal.
来源: Circulation. 2025年151卷7期442-459页
Dilated cardiomyopathy (DCM) appears to be diagnosed twice as often in male than in female patients. This could be attributed to underdiagnosis in female patients or sex differences in susceptibility. Up to 30% of cases have an autosomal dominant monogenic cause, where equal sex prevalence would be expected. The aim of this systematic review, meta-analysis, and population study was to assess the sex ratio in patients with DCM, stratified by genetic status, and evaluate whether this is influenced by diagnostic bias.
3. Independence of Lipoprotein(a) and Low-Density Lipoprotein Cholesterol-Mediated Cardiovascular Risk: A Participant-Level Meta-Analysis.
作者: Harpreet S Bhatia.;Simon Wandel.;Peter Willeit.;Anastasia Lesogor.;Keith Bailey.;Paul M Ridker.;Paul Nestel.;John Simes.;Andrew Tonkin.;Gregory G Schwartz.;Helen Colhoun.;Christoph Wanner.;Sotirios Tsimikas.
来源: Circulation. 2025年151卷4期312-321页
Low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) (Lp[a]) levels are independently associated with atherosclerotic cardiovascular disease (ASCVD). However, the relationship between Lp(a) level, LDL-C level, and ASCVD risk at different thresholds is not well defined.
4. Role of Health Care Professionals in the Success of Blood Pressure Control Interventions in Patients With Hypertension: A Meta-Analysis.
作者: Katherine T Mills.;Samantha S O'Connell.;Meng Pan.;Katherine M Obst.;Hua He.;Jiang He.
来源: Circ Cardiovasc Qual Outcomes. 2024年17卷8期e010396页
Globally, only 13.8% of patients with hypertension have their blood pressure (BP) controlled. Trials testing interventions to overcome barriers to BP control have produced mixed results. Type of health care professional delivering the intervention may play an important role in intervention success. The goal of this meta-analysis is to determine which health care professionals are most effective at delivering BP reduction interventions.
5. Meta-Analysis of Genome-Wide Association Studies Reveals Genetic Mechanisms of Supraventricular Arrhythmias.
作者: Lu-Chen Weng.;Shaan Khurshid.;Amelia Weber Hall.;Victor Nauffal.;Valerie N Morrill.;Yan V Sun.;Joel T Rämö.;Dominik Beer.;Simon Lee.;Girish Nadkarni.;Renee Johnson.;Laura Andreasen.;Anne Clayton.;Clive R Pullinger.;Zachary T Yoneda.;Daniel J Friedman.;Matthew C Hyman.;Renae L Judy.;Allan C Skanes.;Kate M Orland.;Paloma Jordà.;Timothy M Treu.;Matthew T Oetjens.;Rajesh Subbiah.;Jacob P Hartmann.;Heidi T May.;John P Kane.;Tariq Z Issa.;Navid A Nafissi.;Peter Leong-Sit.;Marie-Pierre Dubé.;Carolina Roselli.;Seung Hoan Choi.; .;Jean-Claude Tardif.;Habib R Khan.;Stacey Knight.;Jesper H Svendsen.;Bruce Walker.;Richard Karlsson Linnér.;J Michael Gaziano.;Rafik Tadros.;Diane Fatkin.;Daniel J Rader.;Svati H Shah.;Dan M Roden.;Gregory M Marcus.;Ruth J F Loos.;Scott M Damrauer.;Christopher M Haggerty.;Kelly Cho.;Aarno Palotie.;Morten S Olesen.;Lee L Eckhardt.;Jason D Roberts.;Michael J Cutler.;M Benjamin Shoemaker.;Peter W F Wilson.;Patrick T Ellinor.;Steven A Lubitz.
来源: Circ Genom Precis Med. 2024年17卷3期e004320页
Substantial data support a heritable basis for supraventricular tachycardias, but the genetic determinants and molecular mechanisms of these arrhythmias are poorly understood. We sought to identify genetic loci associated with atrioventricular nodal reentrant tachycardia (AVNRT) and atrioventricular accessory pathways or atrioventricular reciprocating tachycardia (AVAPs/AVRT).
6. Risks of Restrictive Versus Liberal Red Blood Cell Transfusion Strategies in Patients With Cardiovascular Disease: An Updated Meta-Analysis.
作者: Willard N Applefeld.;Verity J Ford.;Irene Cortes-Puch.;Jeffrey Wang.;Junfeng Sun.;Tracy C Shields.;Robert L Danner.;Peter Q Eichacker.;Michael A Solomon.;Harvey G Klein.;Charles Natanson.
来源: Circ Cardiovasc Qual Outcomes. 2024年17卷6期e010957页 7. Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis.
作者: Siddharth M Patel.;Yu Mi Kang.;KyungAh Im.;Brendon L Neuen.;Stefan D Anker.;Deepak L Bhatt.;Javed Butler.;David Z I Cherney.;Brian L Claggett.;Robert A Fletcher.;William G Herrington.;Silvio E Inzucchi.;Meg J Jardine.;Kenneth W Mahaffey.;Darren K McGuire.;John J V McMurray.;Bruce Neal.;Milton Packer.;Vlado Perkovic.;Scott D Solomon.;Natalie Staplin.;Muthiah Vaduganathan.;Christoph Wanner.;David C Wheeler.;Faiez Zannad.;Yujie Zhao.;Hiddo J L Heerspink.;Marc S Sabatine.;Stephen D Wiviott.
来源: Circulation. 2024年149卷23期1789-1801页
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) consistently improve heart failure and kidney-related outcomes; however, effects on major adverse cardiovascular events (MACE) across different patient populations are less clear.
8. Incremental Value of a Metabolic Risk Score for Heart Failure Mortality: A Population-Based Study.
作者: Jungnam Joo.;Joseph J Shearer.;Anna Wolska.;Alan T Remaley.;James D Otvos.;Margery A Connelly.;Maureen Sampson.;Suzette J Bielinski.;Nicholas B Larson.;Hoyoung Park.;Katherine M Conners.;Sarah Turecamo.;Véronique L Roger.
来源: Circ Genom Precis Med. 2024年17卷2期e004312页
Heart failure is heterogeneous syndrome with persistently high mortality. Nuclear magnetic resonance spectroscopy enables high-throughput metabolomics, suitable for precision phenotyping. We aimed to use targeted metabolomics to derive a metabolic risk score (MRS) that improved mortality risk stratification in heart failure.
10. Coronary Angiography, Intravascular Ultrasound, and Optical Coherence Tomography for Guiding of Percutaneous Coronary Intervention: A Systematic Review and Network Meta-Analysis.
作者: Daniele Giacoppo.;Claudio Laudani.;Giovanni Occhipinti.;Marco Spagnolo.;Antonio Greco.;Carla Rochira.;Federica Agnello.;Davide Landolina.;Maria Sara Mauro.;Simone Finocchiaro.;Placido Maria Mazzone.;Nicola Ammirabile.;Antonino Imbesi.;Carmelo Raffo.;Sergio Buccheri.;Davide Capodanno.
来源: Circulation. 2024年149卷14期1065-1086页
Results from multiple randomized clinical trials comparing outcomes after intravascular ultrasound (IVUS)- and optical coherence tomography (OCT)-guided percutaneous coronary intervention (PCI) with invasive coronary angiography (ICA)-guided PCI as well as a pivotal trial comparing the 2 intravascular imaging (IVI) techniques have provided mixed results.
11. Major Facilitator Superfamily Domain Containing 5 Inhibition Reduces Lipoprotein(a) Uptake and Calcification in Valvular Heart Disease.
作者: Maximillian A Rogers.;Francesca Bartoli-Leonard.;Kang H Zheng.;Aeron M Small.;Hao Yu Chen.;Cassandra L Clift.;Takaharu Asano.;Shiori Kuraoka.;Mark C Blaser.;Katelyn A Perez.;Pradeep Natarajan.;Calvin Yeang.;Erik S G Stroes.;Sotirios Tsimikas.;James C Engert.;George Thanassoulis.;Christopher J O'Donnell.;Masanori Aikawa.;Sasha A Singh.;Elena Aikawa.
来源: Circulation. 2024年149卷5期391-401页
High circulating levels of Lp(a) (lipoprotein[a]) increase the risk of atherosclerosis and calcific aortic valve disease, affecting millions of patients worldwide. Although atherosclerosis is commonly treated with low-density lipoprotein-targeting therapies, these do not reduce Lp(a) or risk of calcific aortic valve disease, which has no available drug therapies. Targeting Lp(a) production and catabolism may provide therapeutic benefit, but little is known about Lp(a) cellular uptake.
12. Meta-Analysis of Penetrance and Systematic Review on Transition to Disease in Genetic Hypertrophic Cardiomyopathy.
作者: Constantin-Cristian Topriceanu.;Alexandre C Pereira.;James C Moon.;Gabriella Captur.;Carolyn Y Ho.
来源: Circulation. 2024年149卷2期107-123页
Hypertrophic cardiomyopathy (HCM) is characterized by unexplained left ventricular hypertrophy and is classically caused by pathogenic or likely pathogenic variants (P/LP) in genes encoding sarcomere proteins. Not all subclinical variant carriers will manifest clinically overt disease because penetrance (proportion of sarcomere or sarcomere-related P/LP variant carriers who develop disease) is variable, age dependent, and not reliably predicted.
13. Safety and Efficacy of Ticagrelor Monotherapy in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: An Individual Patient Data Meta-Analysis of TWILIGHT and TICO Randomized Trials.
作者: Usman Baber.;Yangsoo Jang.;Angelo Oliva.;Davide Cao.;Birgit Vogel.;George Dangas.;Samantha Sartori.;Alessandro Spirito.;Kenneth F Smith.;Mattia Branca.;Timothy Collier.;Stuart Pocock.;Marco Valgimigli.;Byeong-Keuk Kim.;Myeong-Ki Hong.;Roxana Mehran.
来源: Circulation. 2024年149卷8期574-584页
Dual antiplatelet therapy with a potent P2Y12 inhibitor coupled with aspirin for 1 year is the recommended treatment for patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). As an alternative, monotherapy with a P2Y12 inhibitor after a short period of dual antiplatelet therapy has emerged as a bleeding reduction strategy.
14. Bivalirudin Versus Heparin During PCI in NSTEMI: Individual Patient Data Meta-Analysis of Large Randomized Trials.
作者: Behnood Bikdeli.;David Erlinge.;Marco Valgimigli.;Adnan Kastrati.;Yaling Han.;Philippe Gabriel Steg.;Rod H Stables.;Roxana Mehran.;Stefan K James.;Enrico Frigoli.;Patrick Goldstein.;Yi Li.;Adeel Shahzad.;Stefanie Schüpke.;Ghazaleh Mehdipoor.;Shmuel Chen.;Björn Redfors.;Aaron Crowley.;Zhipeng Zhou.;Gregg W Stone.
来源: Circulation. 2023年148卷16期1207-1219页
The benefit:risk profile of bivalirudin versus heparin anticoagulation in patients with non-ST-segment-elevation myocardial infarction undergoing percutaneous coronary intervention (PCI) is uncertain. Study-level meta-analyses lack granularity to provide conclusive answers. We sought to compare the outcomes of bivalirudin and heparin in patients with non-ST-segment-elevation myocardial infarction undergoing PCI.
15. Common Variants on FGD5 Increase Hazard of Mortality or Rehospitalization in Patients With Heart Failure From the ASCEND-HF Trial.
作者: Hongsheng Gui.;W H Wilson Tang.;Stephan Francke.;Jia Li.;Ruicong She.;Peter Bazeley.;Naveen L Pereira.;Kirkwood Adams.;Jasmine A Luzum.;Thomas M Connolly.;Adrian F Hernandez.;Candace D McNaughton.;L Keoki Williams.;David E Lanfear.
来源: Circ Heart Fail. 2023年16卷9期e010438页
Heart failure remains a global health burden, and patients hospitalized are particularly at risk, but genetic associates for subsequent death or rehospitalization are still lacking.
16. Temporal Trends and Lesion Sets for Persistent Atrial Fibrillation Ablation: A Meta-Analysis With Trial Sequential Analysis and Meta-Regression.
作者: Arunashis Sau.;Sharan Kapadia.;Sayed Al-Aidarous.;James Howard.;Afzal Sohaib.;Markus B Sikkel.;Ahran Arnold.;Jonathan W Waks.;Daniel B Kramer.;Nicholas S Peters.;Fu Siong Ng.
来源: Circ Arrhythm Electrophysiol. 2023年16卷9期e011861页
Ablation for persistent atrial fibrillation (PsAF) has been performed for over 20 years, although success rates have remained modest. Several adjunctive lesion sets have been studied but none have become standard of practice. We sought to describe how the efficacy of ablation for PsAF has evolved in this time period with a focus on the effect of adjunctive ablation strategies.
17. Racial Differences in Quality of Life in Patients With Heart Failure Treated With Sodium-Glucose Cotransporter 2 Inhibitors: A Patient-Level Meta-Analysis of the CHIEF-HF, DEFINE-HF, and PRESERVED-HF Trials.
作者: Kashvi Gupta.;John A Spertus.;Mary Birmingham.;Kensey L Gosch.;Mansoor Husain.;Dalane W Kitzman.;Bertram Pitt.;Sanjiv J Shah.;James L Januzzi.;Ildiko Lingvay.;Javed Butler.;Mikhail Kosiborod.;David E Lanfear.
来源: Circulation. 2023年148卷3期220-228页
Health status outcomes, including symptoms, function, and quality of life, are worse for Black compared with White patients with heart failure. Sodium-glucose cotransporter 2 inhibitors (SGLT2is) reduce cardiovascular mortality and improve health status in patients with heart failure, but whether the health status benefit of SGLT2is is similar across races is not established. The objective of this study was to compare the treatment effect of SGLT2is (versus placebo) on health status for Black compared with White patients with heart failure.
18. Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF.
作者: Josephine Harrington.;Anthony P Carnicelli.;Kaiyuan Hua.;Lars Wallentin.;Manesh R Patel.;Stefan H Hohnloser.;Robert P Giugliano.;Keith A A Fox.;Ziad Hijazi.;Renato D Lopes.;Sean D Pokorney.;Hwanhee Hong.;Christopher B Granger.
来源: Circulation. 2023年147卷23期1748-1757页
There is uncertainty surrounding the use of direct oral anticoagulants (DOACs) in patients with kidney dysfunction.
19. Oligogenic Architecture of Rare Noncoding Variants Distinguishes 4 Congenital Heart Disease Phenotypes.
作者: Mengyao Yu.;Matthew Aguirre.;Meiwen Jia.;Ketrin Gjoni.;Aldo Cordova-Palomera.;Chad Munger.;Dulguun Amgalan.;X Rosa Ma.;Alexandre Pereira.;Catherine Tcheandjieu.;Christine Seidman.;Jonathan Seidman.;Martin Tristani-Firouzi.;Wendy Chung.;Elizabeth Goldmuntz.;Deepak Srivastava.;Ruth J F Loos.;Nathalie Chami.;Heather Cordell.;Martina Dreßen.;Bertram Mueller-Myhsok.;Harald Lahm.;Markus Krane.;Katherine S Pollard.;Jesse M Engreitz.;Sarah A Gagliano Taliun.;Bruce D Gelb.;James R Priest.
来源: Circ Genom Precis Med. 2023年16卷3期258-266页
Congenital heart disease (CHD) is highly heritable, but the power to identify inherited risk has been limited to analyses of common variants in small cohorts.
20. Long-Term Effect of Weight Regain Following Behavioral Weight Management Programs on Cardiometabolic Disease Incidence and Risk: Systematic Review and Meta-Analysis.
作者: Jamie Hartmann-Boyce.;Annika Theodoulou.;Jason L Oke.;Ailsa R Butler.;Anastasios Bastounis.;Anna Dunnigan.;Rimu Byadya.;Linda J Cobiac.;Peter Scarborough.;F D Richard Hobbs.;Falko F Sniehotta.;Susan A Jebb.;Paul Aveyard.
来源: Circ Cardiovasc Qual Outcomes. 2023年16卷4期e009348页
Behavioral weight management programs (BWMPs) enhance weight loss in the short term, but longer term cardiometabolic effects are uncertain as weight is commonly regained. We assessed the impact of weight regain after BWMPs on cardiovascular risk factors, diabetes, and cardiovascular disease.
|